Centessa has been formed as a biotech conglomerate with $250m in funding following a ten-way merger, including multiple spinouts.
US-based pharmaceutical conglomerate Centessa Pharmaceuticals has been formed by investment firm Medicxi and equipped with $250m in series A financing following a large-scale merger that involved a host of spinouts.
Three spinouts of University of Cambridge – haemophilia treatment developer Apcintex, pulmonary arterial hypertension therapy developer Morphogen-IX and liver and lung diseases drug producer Z-Factor – have been absorbed into Centessa.
The ten-way merger also involved University of Toronto Mississauga’s biopharmaceutical spinout Janpix, kidney…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
